How to buy NuVasive (NUVA) stock

NuVasive, Inc is a medical devices business based in the US. NuVasive shares (NUVA) are listed on the NASDAQ and all prices are listed in US Dollars. NuVasive employs 2,700 staff and has a trailing 12-month revenue of around 0.00.

NuVasive stock price (NASDAQ: NUVA)

Use our graph to track the performance of NUVA stocks over time.

NuVasive shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$68.20
52-week range	$43.11 - $72.61
50-day moving average	$66.23
200-day moving average	$64.34
Wall St. target price	$73.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$1.15

Buy NuVasive shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy NuVasive stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of NuVasive, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NuVasive price performance over time

Historical closes compared with the close of $68.2 from 2021-05-28

1 week (2021-07-15)	N/A
1 month (2021-06-25)	-2.42%
3 months (2021-04-26)	-3.17%
6 months (2021-01-22)	N/A

1 year (2020-07-22)	N/A
2 years (2019-07-22)	N/A
3 years (2018-07-22)	N/A
5 years (2016-07-22)	N/A

Is NuVasive under- or over-valued?

Valuing NuVasive stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NuVasive's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

NuVasive's PEG ratio

NuVasive's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.5442. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into NuVasive's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

NuVasive's EBITDA

NuVasive's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $173.2 million.

The EBITDA is a measure of a NuVasive's overall financial performance and is widely used to measure a its profitability.

NuVasive financials

Revenue TTM	$1.1 billion
Operating margin TTM	3.88%
Gross profit TTM	$729 million
Return on assets TTM	1.18%
Return on equity TTM	-5.8%
Profit margin	-4.71%
Book value	$16.26
Market capitalisation	$3.3 billion

TTM: trailing 12 months

Shorting NuVasive shares

There are currently 3.6 million NuVasive shares held short by investors – that's known as NuVasive's "short interest". This figure is 2.6% up from 3.5 million last month.

There are a few different ways that this level of interest in shorting NuVasive shares can be evaluated.

NuVasive's "short interest ratio" (SIR)

NuVasive's "short interest ratio" (SIR) is the quantity of NuVasive shares currently shorted divided by the average quantity of NuVasive shares traded daily (recently around 555335.15625). NuVasive's SIR currently stands at 6.4. In other words for every 100,000 NuVasive shares traded daily on the market, roughly 6400 shares are currently held short.

However NuVasive's short interest can also be evaluated against the total number of NuVasive shares, or, against the total number of tradable NuVasive shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NuVasive's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 NuVasive shares in existence, roughly 70 shares are currently held short) or 0.0693% of the tradable shares (for every 100,000 tradable NuVasive shares, roughly 69 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against NuVasive.

Find out more about how you can short NuVasive stock.

NuVasive share dividends

We're not expecting NuVasive to pay a dividend over the next 12 months.

NuVasive share price volatility

Over the last 12 months, NuVasive's shares have ranged in value from as little as $43.11 up to $72.61. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NuVasive's is 1.3254. This would suggest that NuVasive's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

NuVasive overview

NuVasive, Inc. , a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. it provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology and its intraoperative neuromonitoring services and support; and specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone. The company also offers reline fixation system that facilitates the preservation and restoration of patient alignment; integrated global alignment platform consisting of Bendini spinal rod bending system that assists with manual rod manipulation for spinal fixation; Lessray that is an image enhancement platform designed to reduce radiation exposure in the operating room, as well as Pulse, which integrates multiple enabling technologies to enhance workflow, reduce variability, and increase the reproducibility of surgical outcomes; and various biologics that are used to aid in the spinal fusion or bone healing process. In addition, it provides MAGEC, a spinal bracing and distraction system, Precice limb lengthening system, and various other products for treating specialized orthopedic procedures; onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries; and cervical artificial disc technology for cervical total disc replacement procedures. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc.

Frequently asked questions

What percentage of NuVasive is owned by insiders or institutions?
Currently 0.596% of NuVasive shares are held by insiders and 109.494% by institutions. How many people work for NuVasive?
Latest data suggests 2,700 work at NuVasive. When does the fiscal year end for NuVasive?
NuVasive's fiscal year ends in December. Where is NuVasive based?
NuVasive's address is: 7475 Lusk Boulevard, San Diego, CA, United States, 92121 What is NuVasive's ISIN number?
NuVasive's international securities identification number is: US6707041058 What is NuVasive's CUSIP number?
NuVasive's Committee on Uniform Securities Identification Procedures number is: 670704105